Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target
Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.
Stocks · News reference
Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.